^(131)I-LPD内辐射治疗原发性肝癌的研究

Internal radiation of ^(131)I-LPD to treat hepatocellular carcinoma

目的研究131I－LPD选择性内辐射治疗原发性肝癌的吸收剂量及其疗效。方法对8例经手术证实不能切除的肝癌患者经肝动脉反复灌注131I－LPD计算癌组织的吸收剂量，观察其疗效。结果8例平均接受了25次内辐射治疗，放射性活废为（529±127）MBq.131主要聚集在肝癌病灶，癌肝放射性计数比值（T／NT）为2．50～8．50（SD5．60±1．78）。癌组织接受的内辐射吸收剂量为（1792±774）cGY。8例中有5例AFP＞500μg／L，，治疗后转为正常。其中4例因癌肿缩小得以再切除。8例的3年生存率为74％，5年生存率为56％。结论131I－LPD经肝动脉灌注是较理想的内辐射治疗肝癌的方法。

Objective To study the results of targeting therapy for hepatocellular carcinoma (HCC)with131 I-lipiodol (131 I-LPD) and estimate the radiate absorbed doses. Method Eight patients with HCCproved unsectable by operation repeatedly received injection of 131I-LPD through hepatic artery. The therapeutic effects and the radiation doses in cancer tissues were obscrved. Results Eight patients with HCC received2. 5 times of internal radiation 0f 131 I-LPD. The radiate activity was 529±127 MBq. 131I-LPD was concentrated in the foci of HCC with a N/NT being 2. 50-8. 50. The absorbed doses of internal radiation in thecancer tissues was 1792±774 cGy. The level of scrum alpha fetoprotein (AFP) was turned to normal aftertreatment in 5 out of the 8 patients with The level of AFP over 500 μg/L prior to operation. Four cases underwent second operation and the tumors were removed because of tumor shrinkage. Three-year survival rate inthe 8 cases was 74% and 5-year survival rate 56 %. Conclusion Injection of 131I-LPD through hepaticartery may be considered as an effective method of selective internal radiation to treat HCC.[